Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates
Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates
复制标题
DOI：
10.1016/j.vaccine.2006.12.031
复制
发表时间：
2007-04-12
期刊：
影响因子：
5.5
通讯作者：
Ambrosino, Donna M.
中科院分区：
文献类型：
--
作者：
Sloan, Susan E.;Hanlon, Cathleen;Ambrosino, Donna M.
狂犬病是一种人畜共患病，每年在全世界造成数百万人感染。中和狂犬病病毒的人单克隆抗体（HuMAb）可能代表了一种可行的人类暴露后预防策略，与目前的人或马狂犬病免疫球蛋白相比具有许多优势。携带人免疫球蛋白基因的转基因小鼠被用来分离中和狂犬病病毒的人单克隆抗体。从一组具有公共卫生意义的广泛分离株中鉴定出几种中和狂犬病病毒变体的HuMAb。HuMAb 17C7是鉴定的最有希望的抗体，因为它中和了所有测试的狂犬病病毒分离株。HuMAb 17C7识别狂犬病病毒糖蛋白上的构象表位，其包括抗原位点III。HuMAb 17 C7在暴露后预防的完善体内模型中保护仓鼠免受致死剂量的狂犬病病毒的侵害。(c)2006爱思唯尔有限公司版权所有。
Rabies is a zoonosis that results in millions of human exposures worldwide each year. Human monoclonal antibodies (HuMAbs) that neutralize rabies virus may represent one viable strategy for post-exposure prophylaxis in humans, and have many advantages over current human or equine rabies immune globulin. Transgenic mice carrying human immunoglobulin genes were used to isolate human monoclonal antibodies that neutralized rabies virus. Several HuMAbs were identified that neutralized rabies virus variants from a broad panel of isolates of public health significance. HuMAb 17C7 was the most promising antibody identified because it neutralized all rabies virus isolates tested. HuMAb 17C7 recognizes a conformational epitope on the rabies virus glycoprotein which includes antigenic site III. HuMAb 17C7 protected hamsters from a lethal dose of rabies virus in a well-established in vivo model of post-exposure prophylaxis. (c) 2006 Elsevier Ltd. All rights reserved.